Home » Stocks » DYAI

Dyadic International, Inc. (DYAI)

Stock Price: $4.85 USD 0.03 (0.62%)
Updated Apr 22, 2021 4:00 PM EDT - Market closed
Market Cap 130.61M
Revenue (ttm) 1.60M
Net Income (ttm) -9.33M
Shares Out 27.55M
EPS (ttm) -0.34
PE Ratio n/a
Forward PE 12.76
Dividend n/a
Dividend Yield n/a
Trading Day April 22
Last Price $4.85
Previous Close $4.82
Change ($) 0.03
Change (%) 0.62%
Day's Open 4.86
Day's Range 4.75 - 5.04
Day's Volume 154,086
52-Week Range 4.56 - 10.98

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Fireside Chat Being Held on Tuesday, May 4th @ 10am Eastern Time Fireside Chat Being Held on Tuesday, May 4th @ 10am Eastern Time

1 day ago - GlobeNewsWire

Bloomberg reported this morning that the world's wealthiest countries are vaccinating 25 times faster than the poorest. As of April 8, 40% of the shots administered have gone to people in 27 nations tha...

1 week ago - OTC PR Wire

Death, Taxes, and Covid shots. The future stretching out in front of us has maybe only these three certainties.

3 weeks ago - OTC PR Wire

Advancing Dyadic ' s proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial To validate C1 produced proteins are safe in humans and accelerate C1 adoption and ...

3 weeks ago - Accesswire

While the pandemic feels “almost over” on many levels, experts believe the fundamental driver – a rapidly mutating coronavirus pathogen with uniquely formidable qualities – is likely, and unfortunately,...

3 weeks ago - OTC PR Wire

JUPITER, Fla., March 29, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, ...

3 weeks ago - GlobeNewsWire

JUPITER, Fla., March 23, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, ...

1 month ago - GlobeNewsWire

Dyadic International is surging today after it announced a Covid vaccine partnership with Medytox, but that isn't the only bullish news for this small cap biotech stock. The post DYAI Stock: Why Covid-1...

1 month ago - InvestorPlace

Odonate Therapeutics, Inc. (NASDAQ: ODT), Dyadic International, Inc. (NASDAQ: DYAI) and Marker Therapeutics, Inc. (NASDAQ: MRKR) are among the early biotech movers in Monday's session. Odonate to Shut S...

Other stocks mentioned: MRKR, ODT
1 month ago - Benzinga

Dyadic International Inc's (NASDAQ: DYAI) initial C1 produced SARS-CoV-2-S-RBD vaccine candidate, DYAI-100, moves towards the first human Phase 1 clinical trial to assess the safety and preliminary effi...

1 month ago - Benzinga

JUPITER, FL / ACCESSWIRE / March 16, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applyin...

1 month ago - Accesswire

Results demonstrate that Dyadic's C1 platform produced record levels of safe and effective vaccines in animal trials and further positions C1 products for potential human clinical trials Results demonst...

1 month ago - GlobeNewsWire

JUPITER, FL / ACCESSWIRE / January 11, 2021 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expres...

3 months ago - Accesswire

Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

This small-cap stock is developing a technology that could revolutionize biotech.

9 months ago - The Motley Fool

Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Dyadic International: The Pandemic Changes Everything

1 year ago - Seeking Alpha

Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Dyadic International, Inc. (NASDAQ: DYAI) shares are trading higher on Thursday, after the company announced its platform is to be used by the Israeli Research Institution to develop a treatment for the...

1 year ago - Benzinga

Monday morning brought a huge sell-off in the market as more and more people are concerned about the growing impact of this new coronavirus.

Other stocks mentioned: AHPI, APT, BCRX, CERS, CODX, INO, LAKE ...
1 year ago - 24/7 Wall Street

Dyadic International: Disrupting Biopharma Delivery And Costs

1 year ago - Seeking Alpha

Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Company’s lead product promises to greatly speed development and reduce costs of producing biologic drugs, which is currently being tested by major collaborators and at least two big pharma players.

1 year ago - Seeking Alpha

About DYAI

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins.... [Read more...]

Industry
Biotechnology
IPO Date
Nov 5, 2004
Stock Exchange
NASDAQ
Ticker Symbol
DYAI
Full Company Profile

Financial Performance

In 2020, DYAI's revenue was $1.60 million, a decrease of -4.71% compared to the previous year's $1.68 million. Losses were -$9.33 million, 12.2% more than in 2019.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for DYAI stock is "Strong Buy" and the 12-month stock price forecast is 11.00.

Price Target
$11.00
Analyst Consensus: Strong Buy